Journal
NATURE BIOTECHNOLOGY
Volume 35, Issue 5, Pages 463-+Publisher
NATURE PORTFOLIO
DOI: 10.1038/nbt.3834
Keywords
-
Categories
Funding
- NIH Director's New Innovator Award Program NIH/NHGRI [1DP2HD084069-01, T32 HG000044]
- NIH/NCI [1U01CA199261-02]
- Stanford ChEM-H
- Walter V. and Idun Berry award
- NIH [2T32CA009302]
- Hubert Shaw and Sandra Lui Stanford Graduate Fellowship
Ask authors/readers for more resources
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring method for calculating genetic interactions (GIs) from CRISPR-deleted gene pairs. We applied CDKO to generate a large-scale human GI map, comprising 490,000 double-sgRNAs directed against 21,321 pairs of drug targets in K562 leukemia cells and identified synthetic lethal drug target pairs for which corresponding drugs exhibit synergistic killing. These included the BCL2L1 and MCL1 combination, which was also effective in imatinib-resistant cells. We further validated this system by identifying known and previously unidentified GIs between modifiers of ricin toxicity. This work provides an effective strategy to screen synergistic drug combinations in high-throughput and a CRISPR-based tool to dissect functional GI networks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available